Babić Tomislav, Mahović Darija
CNS International, 13 Research, Maidenhead, Berks, UK
Coll Antropol. 2008 Dec;32(4):1275-81.
Idiopathic Parkinson's disease (IPD) is the second most common neurodegenerative disorder after Alzheimer's disease. Treatment aims in IPD include the provision of symptomatic relief reduction of functional disability, halting or slowing of the neurodegenerative process, and the prevention of long-term complications by proper initiation of therapy. At present, pharmacotherapeutic strategies allow the amelioration of motor symptoms of IPD only, whereas non-motor manifestations are not helped by dopamine replacement strategies. In addition, levodopa-induced fluctuation and dyskinesia are still challenging, particularly in long-term treatment. Despite advances in pharmacotherapy that have improved quality of life for these patients, the mortality rate remains largely unchanged. Sustained interest in IPD will hopefully allow increased funding of research to develop new and better treatments.
特发性帕金森病（IPD）是仅次于阿尔茨海默病的第二常见神经退行性疾病。IPD的治疗目标包括缓解症状、减少功能残疾、阻止或减缓神经退行性进程以及通过适当启动治疗预防长期并发症。目前，药物治疗策略仅能改善IPD的运动症状，而多巴胺替代策略对非运动表现并无帮助。此外，左旋多巴引起的波动和异动症仍然具有挑战性，尤其是在长期治疗中。尽管药物治疗取得了进展，改善了这些患者的生活质量，但死亡率基本保持不变。对IPD的持续关注有望增加研究资金，以开发新的更好的治疗方法。
